No abstract available
MeSH terms
-
Anti-HIV Agents / adverse effects
-
Anti-HIV Agents / classification
-
Anti-HIV Agents / therapeutic use*
-
CCR5 Receptor Antagonists
-
Cyclohexanes / adverse effects
-
Cyclohexanes / therapeutic use
-
HIV Fusion Inhibitors / adverse effects
-
HIV Fusion Inhibitors / therapeutic use
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV Integrase Inhibitors / adverse effects
-
HIV Integrase Inhibitors / therapeutic use
-
HIV-1 / drug effects*
-
Humans
-
Maraviroc
-
Piperazines / adverse effects
-
Piperazines / therapeutic use
-
Pyrimidines / adverse effects
-
Pyrimidines / therapeutic use
-
Pyrrolidinones / adverse effects
-
Pyrrolidinones / therapeutic use
-
Quinolones / adverse effects
-
Quinolones / therapeutic use
-
Raltegravir Potassium
-
Succinates / adverse effects
-
Succinates / therapeutic use
-
Triazoles / adverse effects
-
Triazoles / therapeutic use
-
Triterpenes / adverse effects
-
Triterpenes / therapeutic use
-
Viral Load
Substances
-
Anti-HIV Agents
-
CCR5 Receptor Antagonists
-
Cyclohexanes
-
HIV Fusion Inhibitors
-
HIV Integrase Inhibitors
-
Piperazines
-
Pyrimidines
-
Pyrrolidinones
-
Quinolones
-
Succinates
-
Triazoles
-
Triterpenes
-
Raltegravir Potassium
-
elvitegravir
-
Maraviroc
-
bevirimat
-
vicriviroc